Neurological Disorders, Depression and Inflammation: Is there a Common Link?

References

• Murray CJ , LopezAD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet349(9063), 1436–1442 (1997).
   PubMed Web of Science ®Google Scholar
• Demyttenaere K , BruffaertsR, Posada-VillaJet al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world Mental Health surveys. JAMA291, 2581–2590 (2004).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) . GonzalezO, BerryJT, McKnight-EilyLRet al.Current depression among adults United States, 2006 and 2008. Morb. Mortal. Wkly. Rep.59, 1229–1235 (2010).
   PubMedGoogle Scholar
• Lepin JP , BrileyM. The increasing burden of depression. Neuropsych. Dis. Treat.7(Suppl 1), 3–7 (2011).
   PubMedGoogle Scholar
• Rozanski A , BlumenthalJA, KaplanJ. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation99, 2192–2217 (1999).
   PubMed Web of Science ®Google Scholar
• Thielscher C , ThielscherS, KostevK. The risk of developing depression when suffering from neurological diseases. Ger. Med. Sci.11(Doc02), doi: 10.3205/000170 (2013).
   PubMedGoogle Scholar
• Selye H . The Story of the Adaptation Syndrome. ACTA Inc. Medical Publishers, Montreal, Canada (1952).
   Google Scholar
• Selye H . The Stress of Life. McGraw-Hill, NY, USA (1956).
   Google Scholar
• McEwen BS . Stress, adaptation, and disease allostasis and allostatic load. Ann. N.Y. Acad. Sci.840(1), 33–44 (1998).
   PubMed Web of Science ®Google Scholar
• Tracey KJ . Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest.117, 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• Thayer JF , LaneRD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol. Psychol.74, 224–242 (2007).
   PubMed Web of Science ®Google Scholar
• Miller AH , MaleticV, RalsonCL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry.65, 732–741 (2009).
   PubMed Web of Science ®Google Scholar
• Khansari PS , SperlaghB. Inflammation in neurological and psychiatric diseases. Inflammopharmacology20, 103–107 (2012).
   PubMedGoogle Scholar
• Lyman M , LloydDG, JiX, VizcaychipiMP, MaD. Neuroinflammation: the role and consequences. Neurosci. Res.79, 1–12 (2014).
   PubMed Web of Science ®Google Scholar
• Chakraborty S , KaushikDK, GuptaM, BasuA. Inflammasome signaling at the heart of central nervous system pathology. J. Neurosci. Res.88(8), 1615–1631 (2010).
   PubMed Web of Science ®Google Scholar
• Shaw PJ , McDermottMF, KannegantiTD. Inflammasomes and autoimmunity. Trends Mol. Med.17(2), 57–64 (2011).
   PubMed Web of Science ®Google Scholar
• Singhal G , JaehneEJ, CorriganFet al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci.8(15), 1–13 (2014).
   PubMedGoogle Scholar
• Kipp M , NorkuteA, JohannSet al. Brain-region-specific astroglial responses in vitro after LPS exposure. J. Mol. Neurosci.35, 235–243 (2008).
   PubMed Web of Science ®Google Scholar
• Maes M , BosmansE, SuyEet al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiat. Scand.84, 379–386 (1991).
   PubMed Web of Science ®Google Scholar
• Maes M . Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry19, 11–38 (1995).
   PubMed Web of Science ®Google Scholar
• Wichers M , MaesM. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol.5, 375–388 (2002).
   PubMed Web of Science ®Google Scholar
• Lee KM , KimYK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol.6, 1298–1304 (2006).
   PubMed Web of Science ®Google Scholar
• Maes M , BosmansE, MeltzerHYet al. Interleukin-1beta: a putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry 150, 1189–1193 (1993).
   PubMed Web of Science ®Google Scholar
• Maes M , der PlankenV, Van GastelAet al. Blood coagulation and platelet aggression in major depression. J. Affect. Disord.40, 35–40 (1996).
   PubMed Web of Science ®Google Scholar
• Kop WJ , GottdienerJS, TangenCMet al. Inflammation and coagulation factors on persons>65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am. J. Cardiol.89, 419–424 (2002).
   PubMed Web of Science ®Google Scholar
• Musselman DL , MillerAH, PorterMRet al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry158, 1252–1257 (2001).
   PubMed Web of Science ®Google Scholar
• Lindqvist D , HallS, SurovaYet al. Cerebrospinal fluid inflammatory markers in Parkinson's disease associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun.33, 183–189 (2013).
   PubMed Web of Science ®Google Scholar
• Collins L , ToulouseA, ConnorTJ, NolanYM. Contributions of cental and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology62, 2154–2168 (2012).
   PubMed Web of Science ®Google Scholar
• Litteljohn D , HayleyS. Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach. Methods Mol. Biol.934, 121–144 (2012).
   PubMedGoogle Scholar
• Connor TJ , LeonardBE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci.62, 583–606 (1998).
   PubMed Web of Science ®Google Scholar
• Leonard BE . Brain cytokines and the psychopathology of depression. In: Antidepressants. LeonardBE ( Ed.). Basel, Birkhauser Verlag, 109–120 (2001).
   Google Scholar
• Castanon N , LeonardBE, NeveuPJ, YirmiyaR. Effects of antidepressants on cytokine production and actions. Brain Behav. Immun.16, 569–574 (2002).
   PubMed Web of Science ®Google Scholar
• Leonard BE , MyintA. Inflammation and depression: is there a causal connection with dementia?Neutox. Res.10, 149–160 (2006).
   Google Scholar
• von Känel R , HeppU, KraemerBet al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res.41, 744–52 (2006).
   PubMed Web of Science ®Google Scholar
• Maes M . The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett.29, 287–291 (2008).
   PubMed Web of Science ®Google Scholar
• Halaris A . Inflammation, heart disease and depression. Curr. Psychiatry Rep.15, 400 (2013).
   PubMed Web of Science ®Google Scholar
• Thomas AJ , DavisS, MorrisCet al. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry162, 175–177 (2005).
   PubMed Web of Science ®Google Scholar
• Tuglu C , KaraSH, CaliyurtOet al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berlin)170, 429–433 (2003).
   PubMed Web of Science ®Google Scholar
• Alesci S , MartinezPE, KelkarS. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab.90, 2522–2530 (2005).
   PubMed Web of Science ®Google Scholar
• Capuron L , MillerAH. Cytokines and psychopathology: lessons from interferon-alpha. Bihiatryol. Psyc.56, 819–824 (2004).
   Google Scholar
• Capuron L , DantzerR. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun.17(Suppl. 1), S119–124 (2003).
   PubMedGoogle Scholar
• Musselman DL , LawsonDH, GumnickJF. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med.344, 961–966 (2001).
   PubMed Web of Science ®Google Scholar
• Piletz J , HalarisA, IqbalOet al. Pro-inflammatory biomarkers in depression: effect of venlafaxine. World J. Biol. Psychiatry10, 313–323 (2009).
   PubMed Web of Science ®Google Scholar
• Anda R , WilliamsonD, JonesDet al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology4, 285–294 (1993).
   PubMed Web of Science ®Google Scholar
• Kamphuis MH , KalmijnS, TijhuisMAet al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur. J. Cardiovasc. Prev. Rehabil.13, 199–206 (2006).
   PubMedGoogle Scholar
• Pratt LA , FordDE, CrumRMet al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation94, 3123–3129 (1996).
   PubMed Web of Science ®Google Scholar
• Di Iorio A , FerrucciL, SparvieriEet al. Serum IL-1βeta levels in health and disease: a population-based study, ‘The InCHIANTI study’. Cytokine22(6), 198–205 (2003).
   PubMed Web of Science ®Google Scholar
• Biasucci LM . CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation110, e560–567 (2004).
   PubMed Web of Science ®Google Scholar
• Maes M . Introduction to the special section. Int. J. Neuropsychopharmacol.5, 329–331 (2002).
   PubMedGoogle Scholar
• Dantzer R . Cytokine-induced sickness behavior: mechanisms and implications. Ann. N.Y. Acad. Sci.933, 222–234 (2001).
   PubMed Web of Science ®Google Scholar
• Vollmer-Conna U , FazouC, CameronBet al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol. Med.34, 1289–1297 (2004).
   PubMed Web of Science ®Google Scholar
• Smith RS . The macrophage theory of depression. Med. Hypotheses35(4), 298–306 (1991).
   PubMed Web of Science ®Google Scholar
• Ur E , WhitePD, GrossmanA. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur. Arch. Psychiatry Clin. Neurosci.241(5), 317–322 (1992).
   PubMed Web of Science ®Google Scholar
• Lett HS , BlumenthalJA, BabyakMAet al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom. Med.66, 305–315 (2004).
   PubMed Web of Science ®Google Scholar
• Lanquillon S , KriegJC, Bening-Abu-ShachU, VedderH. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology22, 370–379 (2000).
   PubMed Web of Science ®Google Scholar
• Kubera M , LinAH, KenisGet al. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol.21, 199–206 (2001).
   PubMed Web of Science ®Google Scholar
• Kubera M , KenisG, BosmansEet al. Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol.4, 185–192 (2004).
   PubMed Web of Science ®Google Scholar
• Kenis G , MaesM. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol.5, 401–412 (2002).
   PubMed Web of Science ®Google Scholar
• Himmerich H , BinderEB, KünzelHEet al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol. Psychiatry60, 882–888 (2006).
   PubMed Web of Science ®Google Scholar
• Janssen DG , CaniatoRN, VersterJC, BauneBT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol.25, 201–215 (2010).
   PubMed Web of Science ®Google Scholar
• Müller N , SchwarzMJ, DehningSet al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry11, 680–684 (2006).
   PubMed Web of Science ®Google Scholar
• Hackett ML , YapaC, ParagV, AndersonCS. Frequency of depression after stroke: a systematic review of observational studies. Stroke36, 1330–1340 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson RG . Post-stroke depression: prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry54, 376–387 (2003).
   PubMed Web of Science ®Google Scholar
• Linden T , BlomstrandC, SkoogI. Depressive disorders after 20 months in elderly stroke patients: a case–control study. Stroke38, 1860–1863 (2007).
   PubMed Web of Science ®Google Scholar
• Feng C , Min FangM, LiuXY. The neurobiological pathogenesis of post-stroke depression. Sci. World J.2014, doi: 10.1155/2014/521348 (2014).
   Google Scholar
• Kubera M , HolanV, MathisonR, MaesM. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology25, 785–797 (2000).
   PubMed Web of Science ®Google Scholar
• Lucassen PJ , FuchsE, Cze'hB. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol. Psychiatry55, 789–796 (2004).
   PubMed Web of Science ®Google Scholar
• Pascoe MC , CrewtherSG, CareyLM, CrewtherDP. Inflammation and depression: why post-stroke depression may be the norm and not the exception. Int. J. Stroke6, 128–135 (2011).
   PubMed Web of Science ®Google Scholar
• Hirsch EC , HunotS. Neuroinflammation in Parkinson's disease: a target for neuroprotection?Lancet Neurol.8, 382–397 (2009).
   PubMed Web of Science ®Google Scholar
• Tansey MG , GoldbergMS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis.37(3), 510–518 (2010).
   PubMed Web of Science ®Google Scholar
• Gao HM , JiangJ, WilsonBet al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem.81(6), 1285–1297 (2002).
   PubMed Web of Science ®Google Scholar
• Aizenstein HJ , NebesRD, SaxtonJAet al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol.65, 1509–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston H , BoutinH, AllanSM. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans.39, 886–890 (2011).
   PubMed Web of Science ®Google Scholar
• Cavanagh C , Colby-MilleyJ, FarsoMet al. Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer's disease: focus on TNF-α and IL-1β. Future Neurol.6(6), 757–769 (2011).
   Google Scholar
• Sudduth TL , SchmittFA, NelsonPT, WilcockDM. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging34, 1051–1059 (2013).
   PubMedGoogle Scholar
• Hollingworth P , HaroldD, JonesLet al. Alzheimer's disease genetics: current knowledge and future challenges. Int. J. Geriatr. Psychiatry26, 793–802 (2011).
   PubMed Web of Science ®Google Scholar
• Liu L , ChanC. The role of inflamma some in Alzheimer's disease. Ageing Res. Rev.15, 6–15 (2014).
   PubMed Web of Science ®Google Scholar
• Barber R . Inflammatory signaling in Alzheimer's disease and depression. Cleve. Clin. J. Med.78, S47–49 (2011).
   PubMedGoogle Scholar
• Christmas DM , PotokarJP, DaviesSJC. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neurpsych. Dis. Treat.7, 431–439 (2011).
   PubMed Web of Science ®Google Scholar
• Myint AM , KimYK, VerkerkRet al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord.89(1), 143–151 (2007).
   Google Scholar
• Myint AH , KimYK. Cytokine-serotonin interaction through IDO; a neurodegeneration hypothesis of depression. Med. Hypotheses61(5–6), 519–525 (2003).
   PubMed Web of Science ®Google Scholar
• Miller CL , LlenosIC, DulayJR, WeisS. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res.1073–1074, 25–37 (2006).
   PubMed Web of Science ®Google Scholar
• Myint AM , KimYK, VerkerkRet al. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord.102(1–3), 65–72 (2007).
   PubMed Web of Science ®Google Scholar
• Steiner J , WalterM, GosTet al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8(94), (2011).
   PubMedGoogle Scholar
• Nizri E , WirguinI, BrennerT. The role of cholinergic balance perturbation in neurological diseases. Drug News Perspect.20(7), 421–9 (2007).
   PubMedGoogle Scholar
• Brenner T , NizriE, Irony-Tur-SinaiMet al. Acetylcholinesterase inhibitors and cholinergic modulation in myasthenia gravis and neuroinflammation. J. Neuroimmunol.201–202, 121–127 (2008).
   PubMed Web of Science ®Google Scholar
• Nizri E , BrennerT. Modulation of inflammatory pathways by the immune cholinergic system. Amino Acids45(1), 73–85 (2013).
   PubMed Web of Science ®Google Scholar
• Lugaresi A , Di IorioA, IarloriCet al. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp. Gerontol.39(4), 653–657 (2004).
   PubMed Web of Science ®Google Scholar
• Gambi F , RealeM, IarloriCet al. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol.24(3), 314–321 (2004).
   PubMed Web of Science ®Google Scholar
• Reale M , IarloriC, GambiFet al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J. Neuroimmunol.148(1–2), 162–171 (2004).
   PubMed Web of Science ®Google Scholar
• Matsuwaki T , KayasugaY, YamanouchiK, NishiharaM. Maintenance of gonadotropin secretion by glucocorticoids under stress conditions through the inhibition of prostaglandin synthesis in the brain. Endocrinology147(3), 1087–1093 (2006).
   PubMed Web of Science ®Google Scholar
• Ma Y , MatsuwakiT, YamanouchiK, NishiharaM. Cyclooxygenase-2-related signaling in the hypothalamus plays differential roles in response to various acute stresses. Brain Res.1508, 23–33 (2013).
   PubMed Web of Science ®Google Scholar
• Cryer B , DuboisA. The advent of highly selective inhibitors of cyclooxygenase – a review. Prostaglandins Other Lipid Mediat.56(5–6), 341–361 (1998).
   PubMed Web of Science ®Google Scholar
• Nery FG , MonkulES, HatchJPet al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol.23(2), 87–94 (2008).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S , JafariS, RaisiFet al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety26(7), 607–611 (2009).
   PubMed Web of Science ®Google Scholar
• Müller N , StrassnigM, SchwarzMJet al. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin. Investig. Drugs13(8), 1033–1044 (2004a).
   PubMed Web of Science ®Google Scholar
• Müller N , UlmschneiderM, ScheppachCet al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci.254(1), 14–22 (2004b).
   PubMed Web of Science ®Google Scholar
• Riedel M , StrassnigM, SchwarzMJ, MullerN. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs19(10), 805–819 (2005).
   PubMed Web of Science ®Google Scholar
• Aisen PS . The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol.1, 279–284 (2002).
   PubMed Web of Science ®Google Scholar
• Gao HM , LiuB, ZhangW, HongJS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci.24, 395–401 (2003).
   PubMed Web of Science ®Google Scholar
• Miyamoto K , MiyakeS, MizunoMet al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain129, 1984–1992 (2006).
   PubMed Web of Science ®Google Scholar
• Aisen PS , SchaferKA, GrundmanMet al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression. JAMA289(21), 2819–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Esposito E , Di MatteoV, BenignoAet al. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol.205(2), 295–312 (2007).
   PubMed Web of Science ®Google Scholar
• Vlad SC , MilerDR, KowallNW, FelsonDT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology70, 1672–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Minghetti L . Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol.63(9), 901–910 (2004).
   PubMed Web of Science ®Google Scholar
• Barger SW , HörsterD, FurukawaKet al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA92, 9328–9332 (1995).
   PubMed Web of Science ®Google Scholar
• Bruce AJ , BolingW, KindyMSet al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med.2, 788–794 (1996).
   PubMed Web of Science ®Google Scholar
• Tobinick E , GrossH, WeinbergerA, CohenH. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med. Gen. Med.8(2), 25 (2006).
   PubMedGoogle Scholar
• Ferger B , LengA, MuraAet al. Genetic ablation of tumor necrosis factor-alpha (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem.89, 822–833 (2004).
   PubMed Web of Science ®Google Scholar
• Tweedie D , SambamurtiK, GreigNH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res.4(4), 378–385 (2007).
   PubMed Web of Science ®Google Scholar
• Raison CL , RutherfordRE, WoolwineBJet al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry70(1), 31–41 (2013).
   PubMed Web of Science ®Google Scholar
• Devaraj S , RogersJ, JialalI. Statins and biomarkers of inflammation. Curr. Atheroscler. Rep.9(1), 33–41 (2007).
   PubMedGoogle Scholar